Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.
Explore this paper's citation graph
Summary
Clinically approved kinase inhibitors and the emergence of resistance in leukemia, melanoma, lung and breast tumors are reviewed, and parallel lines in terms of secondary mutations and compensatory mechanisms are drawn.
- Type
- review
- Published
- 2016-02-01
- Cited by
- 42
- References
- 169
- OpenAlex
- https://openalex.org/W1948348021
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:11408443
Keywords
Biology, Kinase, Cancer research, Cancer, Tyrosine kinase
References
- Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung Cancers
- Future options for ALK-positive non-small cell lung cancer.
- Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.
- Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
- PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models
- ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options
- Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
- FDA-approved small-molecule kinase inhibitors.
- A historical overview of protein kinases and their targeted small molecule inhibitors.
- EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
- Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
- Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
- Patient-derived Models of Acquired Resistance Can Identify Effective Drug Combinations for Cancer
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
- Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC
Cited by
- The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies
- FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance
- The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein*
- Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).
- Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma
- Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?
- Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
- Chemotherapeutics‐resistance “arms” race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer
- What’s new in chemotherapy for non-small cell lung cancer?
- Emerging functions of the EGFR in cancer
- An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
- A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways
- Cancer Immunotherapy: The Dawn of Antibody Cocktails.
- Resistance to ALK targeting therapies as a gradual Darwinian adaptation to inhibitor specific selective pressures
- Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer
- Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy
- Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
- Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
- Overcoming Compensatory Mechanisms toward Chronic Drug Administration to Ensure Long-Term, Sustainable Beneficial Effects
- Chemopreventive Property of Sencha Tea Extracts towards Sensitive and Multidrug-Resistant Leukemia and Multiple Myeloma Cells
Related papers
- Abstract PL04-03: Cell signaling by receptor tyrosine kinases: From basic principles to cancer therapy
- Receptor tyrosine kinase structure and function in health and disease
- High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets
- Alternative dimerization of receptor tyrosine kinases with signal transduction through a cellular membrane
- Introductory Editorial: Tyrosine Kinases in Cancer
- Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension
- Computational Design of Druglike Allosteric Inhibitors of AXL and MET Receptor Tyrosine Kinases
- Conservation and Early Expression of Zebrafish Tyrosine Kinases Support the Utility of Zebrafish as a Model for Tyrosine Kinase Biology
- Receptor tyrosine kinases: the main targets for new anticancer therapy.